ACM
CAPR icon

ADAR1 Capital Management’s Capricor Therapeutics CAPR Stock Holding History

ADAR1 Capital Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-95,000
Closed -$1.31M – 219
2024
Q4 		$1.31M Buy
+95,000
New +$1.66M 0.26% 67

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ADAR1 Capital Management's CAPR Position: Q2 2026 in Review

ADAR1 Capital Management held its Capricor Therapeutics (CAPR) position steady in Q2 2026 at 90,593 shares worth $2.18M. The position accounts for 0.1% of the portfolio, ranked #139.

ADAR1 Capital Management first reported a position in CAPR in Q3 2024 and has held it in 4 quarters since. The position peaked at $2.75M in Q1 2026. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • ADAR1 Capital Management held 90,593 shares of Capricor Therapeutics worth $2.18M as of Q2 2026.
  • ADAR1 Capital Management left its Capricor Therapeutics share count unchanged in Q2 2026.
  • Capricor Therapeutics made up 0.1% of ADAR1 Capital Management's portfolio in Q2 2026, its #139 holding.
  • ADAR1 Capital Management first reported a position in Capricor Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • ADAR1 Capital Management's Capricor Therapeutics position peaked at $2.75M in Q1 2026.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.